Learning the lessons of antitumour necrosis factor therapy-associated psoriasis.

Psoriasis or psoriasiform skin lesions, as an adverse effect of treatment with antitumor necrosis factor antibody therapy, have been described relatively recently. Patients with these lesions have no personal or family history of psoriasis. In a small number of cases, an association with Chlamydia has been suggested. The skin lesions may disappear on discontinuation of therapy or, in the majority of cases, even if antitumor necrosis factor antibody therapy is continued. Therefore, withdrawal of therapy is generally not required for this adverse effect but referral to a dermatologist may be desirable for confirmation of diagnosis and treatment.

[1]  W. Dixon,et al.  Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register , 2008, Annals of the rheumatic diseases.

[2]  R. Panaccione,et al.  Hepatosplenic T cell lymphoma in inflammatory bowel disease , 2008, Gut.

[3]  J. S. Henning,et al.  Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. , 2008, Arthritis and rheumatism.

[4]  F. Aubin,et al.  Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy. , 2008, Joint, bone, spine : revue du rhumatisme.

[5]  A. Zinsmeister,et al.  Risk factors for opportunistic infections in patients with inflammatory bowel disease. , 2008, Gastroenterology.

[6]  J. Carter,et al.  Psoriasiform lesions induced by tumour necrosis factor antagonists: a skin-deep medical conundrum , 2008, Annals of the rheumatic diseases.

[7]  K. Reich,et al.  Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases , 2008, Archives of Dermatological Research.

[8]  P. Rutgeerts,et al.  Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study , 2007, Gut.

[9]  B. Thiers Psoriasis and Pustular Dermatitis Triggered by TNF-α Inhibitors in Patients With Rheumatologic Conditions , 2008 .

[10]  G. Haroske,et al.  Tumor Necrosis Factor-α Inhibitor-Induced Psoriasis or Psoriasiform Exanthemata , 2008 .

[11]  G. Haroske,et al.  Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. , 2008, American journal of clinical dermatology.

[12]  S. Lepreux,et al.  Psoriasiform Eruptions During Anti–TNF-α Treatment: Psoriasis or Not? , 2007 .

[13]  L. Fry,et al.  Triggering psoriasis: the role of infections and medications. , 2007, Clinics in dermatology.

[14]  S. Lepreux,et al.  Psoriasiform eruptions during anti TNF-alpha treatment: psoriasis or not? , 2007, Archives of dermatology.

[15]  A. Taïeb,et al.  Psoriasiform drug eruptions under anti-TNF treatment of arthritis are not true psoriasis. , 2007, Acta dermato-venereologica.

[16]  W. Sandborn,et al.  Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  R. Inman,et al.  Early cytokine profiles in the joint define pathogen clearance and severity of arthritis in Chlamydia-induced arthritis in rats. , 2006, Arthritis and rheumatism.

[18]  G. Lichtenstein Progressive Multifocal Leukoencephalopathy After Natalizumab Therapy for Crohn's Disease , 2006 .

[19]  U. Kajermo,et al.  Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor‐α in the normal palmar eccrine sweat duct? , 2005, The British journal of dermatology.

[20]  A. Silman,et al.  The British Society for Rheumatology Biologics Register , 2005, Annals of the rheumatic diseases.

[21]  O. Boyman,et al.  Plasmacytoid predendritic cells initiate psoriasis through interferon-α production , 2005, The Journal of experimental medicine.

[22]  V. Pascual,et al.  Cross-regulation of TNF and IFN-¿ in autoimmune diseases , 2005 .

[23]  I. Elefsiniotis,et al.  Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. , 2005, European journal of dermatology : EJD.

[24]  V. Pascual,et al.  Cross-regulation of TNF and IFN-alpha in autoimmune diseases. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Gottlieb,et al.  Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. , 2004, Journal of the American Academy of Dermatology.

[26]  E. Fonseca,et al.  Psoriasiform Eruption Induced by Infliximab , 2004, The Annals of pharmacotherapy.

[27]  D. Baeten,et al.  Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? , 2003, Annals of the rheumatic diseases.

[28]  J. Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. , 2001, The New England journal of medicine.

[29]  M. Wiselka,et al.  Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C , 2000, Postgraduate medical journal.

[30]  M. Gumbs,et al.  Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis , 2000 .

[31]  H. Mcdevitt,et al.  The role of TNFα and related cytokines in the development and function of the autoreactive T-cell repertoire , 1997 .

[32]  G. Watkinson,et al.  Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis , 1982, The British journal of dermatology.